References
- Dunning-DaviesBMParkerAAnnual review of children with neurofibromatosis type 1Arch Dis Child Educ Pract Ed201610110211126486853
- GómezMBatistaOMolecular diagnosis as a strategy for differential diagnosis and at early ages of neurofibromatosis type 1 (NF1)Rev Med Chil2015143101320133026633276
- KorfBRDiagnosis and management of neurofibromatosis type 1Curr Neurol Neurosci Rep20011216216711898512
- TakaharaKKamimuraMNakagawaHUchiyamaSChanges in biochemical markers of bone in patients with insufficiency fracturesJ Bone Miner Metab20042261862515490274
- Brunetti-PierriNDotySBHicksJGeneralized metabolic bone disease in neurofibromatosis type IMol Genet Metab200894110511118289904
- TuckerTSchnabelCHartmannMBone health and fracture rate in individuals with neurofibromatosis 1 (NF1)J Med Genet200946425926519066167
- PetramalaLGiustiniSZinnamoscaLBone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease)Arch Dermatol Res2012304432533122120694
- HeerväEPeltonenSSvedströmEAroHTVäänänenKPeltonenJOsteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitroBone201250379880322226973
- HeerväEHuilajaLLeinonenPPeltonenSPeltonenJFollow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 monthsCalcif Tissue Int201494660861224390519
- BenlidayiICOrtacEAKozanogluERisedronate therapy for neurofibromatosis type 1-related low bone mass: a stitch in time saves nineActa Clin Belg201570213013225338093
- DiédhiouDCunyTSarrANorou DiopSKleinMWeryhaGEfficacy and safety of denosumab for the treatment of osteoporosis: a systematic reviewAnn Endocrinol (Paris)201576665065726639186
- KamimuraMNakamuraYIkegamiSUchiyamaSKatoHTaguchiASignificant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patientsOsteoporos Int20172855956627650642
- WhitakerMGuoJKehoeTBensonGBisphosphonates for osteoporosis: where do we go from here?N Engl J Med2012366222048205122571168
- VasikaranSEastellRBruyèreOMarkers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standardsOsteoporos Int201122239142021184054